{"id":"W3129325639","doi":"10.1016/j.jaad.2021.02.028","title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","year":2021,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Innovaderm (Canada)","funders":"Eli Lilly and Company; Intel Corporation","keywords":"Medicine; Atopic dermatitis; Randomized controlled trial; Dermatology; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00118485,0.0008242688,0.001893072,0.0002575896,0.0004794217,0.001017235,0.0007150862,0.000876036,0.004032873],"category_scores_gemma":[0.001006563,0.0002970021,0.001827345,0.0004995646,0.0005788269,0.0005578463,0.0002311566,0.002217207,0.0004308028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002903148,"about_ca_system_score_gemma":0.002976511,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03743357,"about_ca_topic_score_gemma":0.1447125,"domain_scores_codex":[0.9996382,0.000115531,0.00002000716,0.00006287657,0.0000588213,0.0001044734],"domain_scores_gemma":[0.999474,0.00009633466,0.00009252079,0.00001884429,0.00007070372,0.0002476072],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.869574,0.005140698,0.006135117,0.001936087,0.006112052,0.0001502457,0.0001408898,0.0008797158,0.004941178,0.0002787529,0.01089217,0.09381906],"study_design_scores_gemma":[0.9309883,0.03303176,0.0261721,0.0001986905,0.003954214,0.0001840918,0.0001755603,0.0008487222,0.0005256826,0.0002078129,0.003671778,0.00004138609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.959838,0.02894371,0.0003302504,0.002017635,0.0005276187,0.001366576,0.002497114,0.0001180911,0.004361067],"genre_scores_gemma":[0.9819542,0.01004529,0.0006620555,0.001863653,0.0002047665,0.0004617625,0.002629673,0.00001839127,0.002160354],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9625664,"threshold_uncertainty_score":0.07443136,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01039711786219512,"score_gpt":0.276569757015411,"score_spread":0.2661726391532159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}